Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew L Flint

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?Matthew L Flint, Maureen E Byrne, Claire F Friedman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 22, 2026
Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancerMatthew L Flint, Anna Shvygin, Paul Johannet, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?Matthew L Flint, Maureen E Byrne, Claire F Friedman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 22, 2026
Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancerMatthew L Flint, Anna Shvygin, Paul Johannet, et al.
Pageof 1